ARIAD Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals

ARIA 23.99

0.0%

Feb 17 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: GregorioAllegri	12/23/2015 2:09:58 PM
	Read Replies (1) of 4474

PPAR agonists + imatinib give complete control of CML by activating quiescent stem cells: ncbi.nlm.nih.gov Ponatinib is a poor choice for first or second line CML because of the side effects except when the T315I mutation is present. Ponatinib might be the first choice for combo with PPAR agonists because (a) it is faster than other TKIs to reach CMR and (b) it controls all known mutations. Use until sustained CMR achieved for x number of weeks. Discontinue ponatinib unless disease shows up again (avoiding effects on the vascular system due to inhibition of angiogenesis and fibroblasts. If it works, a real bummer for pharma companies wanting to make big bucks on chronic treatments. Ponatinib is a poor chronic treatment (last resort) but may be the cure (speculation.) Wonder if use of PPAR agonists is associated with onset of cancer... (guess I can google it) GA

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next